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Annually around 1 million patients receive a total hip or total 
knee prosthesis in the United States and over 190,000 hip 
and knee replacements are performed in England and Wales 
(Maradit et al. 2015, National Joint Registry for England and 
Wales 2018). The incidences of prosthetic replacement of the 
hip and knee are expected to increase (Kurtz et al. 2014). Pros-
thetic joint infection (PJI) following total hip or knee arthro-
plasty and the treatment thereof are catastrophic for patients 
and pose tremendous costs to healthcare systems (Poultsides 
et al. 2010, Zmistowski et al. 2013, Moore et al. 2015). Peri-
operative antibiotic prophylaxis remains an effective method 
of reducing the risk of PJI (Illingworth et al. 2013, Thornley et 
al. 2015). The type and duration of antibiotic prophylaxis are 
subject to debate.
Both single-dose and multiple-dose antibiotic prophy-
laxis regimens have been advocated with comparable results 
(Thornley et al. 2015, Tan et al. 2019). The recommendations 
provided by the Second International Consensus Meeting of 
the MusculoSkeletal Infection Society (MSIS) and the Euro-
pean Bone and Joint Infection Society (EBJIS) advise that 
antibiotic prophylaxis should be administered 30–60 minutes 
before incision and discontinued within 24 hours after sur-
gery (Hansen et al. 2014, Parvizi and Gehrke 2018). Large 
variation in prophylaxis regimens has been observed in the 
United Kingdom (Hickson et al. 2015). The Dutch national 
orthopedic association advises administration of antibiotic 
prophylaxis using a first- or second-generation cephalosporin 
starting 30–60 minutes preoperatively and discontinuing the 
antibiotic prophylaxis within 24 hours (Swierstra et al. 2009, 
Nederlandse Orthopaedische Vereniging 2018). The World 
Health Organization and, in the USA, the Centers for Dis-
ease Control and Prevention (CDC) recommend against the 
Background and purpose — The optimal type and dura-
tion of antibiotic prophylaxis for primary arthroplasty of the 
hip and knee are subject to debate. We compared the risk of 
complete revision (obtained by a 1- or 2-stage procedure) for 
periprosthetic joint infection (PJI) after primary total hip or 
knee arthroplasty between patients receiving a single dose 
of prophylactic antibiotics and patients receiving multiple 
doses of antibiotics for prevention of PJI.
Patients and methods — A cohort of 130,712 primary 
total hip and 111,467 knee arthroplasties performed between 
2011 and 2015 in the Netherlands was analyzed. We linked 
data from the Dutch arthroplasty register to a survey col-
lected across all Dutch institutions on hospital-level antibi-
otic prophylaxis policy. We used restricted cubic spline Pois-
son models adjusted for hospital clustering to compare the 
risk of revision for infection according to type and duration 
of antibiotic prophylaxis received.
Results — For total hip arthroplasties, the rates of revision 
for infection were 31/10,000 person-years (95% CI 28–35), 
39 (25–59), and 23 (15–34) in the groups that received mul-
tiple doses of cefazolin, multiple doses of cefuroxime, and 
a single dose of cefazolin, respectively. The rates for knee 
arthroplasties were 27/10,000 person-years (95% CI 24–31), 
40 (24–62), and 24 (16–36). Similar risk of complete revi-
sion for infection among antibiotic prophylaxis regimens was 
found when adjusting for confounders.
Interpretation — In a large observational cohort we 
found no apparent association between the type or duration 
of antibiotic prophylaxis and the risk of complete revision 
for infection. This does question whether there is any advan-
tage to the use of prolonged antibiotic prophylaxis beyond a 
single dose.
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use of postoperative continuation of antibiotic prophylaxis 
and advocate for a single dose of antibiotics delivered preop-
eratively (Berrios-Torres et al. 2017). This recommendation is 
vehemently challenged by the American Association of Hip 
and Knee Surgeons and the International Consensus Meeting, 
which encourage their members to proceed with the current 
common practice of multiple-dose antibiotic prophylaxis pro-
tocols until more evidence is available (Yates 2018).
We compared the risk of complete revision for infection 
in the 1st year following primary hip and knee arthroplasty 
according to the perioperatively administered antibiotic pro-
phylaxis regimen by using data from the Dutch Arthroplasty 
Register (LROI). 
Patients and methods
This study was structured using the STROBE guideline. In 
this observational cohort study, we report analyses of data 
for the Netherlands from the Dutch Arthroplasty Register 
(LROI) between January 1, 2011 and December 31, 2015. 
We included in the study all patients who had a primary hip 
or knee replacement during this period. Patient consent was 
obtained for data collection and linkage by the LROI. Using 
data on patient level was not possible due to the legislation of 
the General Data Protection Regulation.
In the absence of individual patient-level data on antibi-
otic prophylaxis, we performed a national audit of hospital 
perioperative antibiotic prophylaxis regimens in the Nether-
lands (Veltman et al. 2018). All 99 Dutch hospitals or clin-
ics performing primary total hip arthroplasty (THA) or total 
knee arthroplasty (TKA) were contacted and all completed a 
survey to identify the existence of treatment protocols con-
cerning primary joint replacement, the existence of protocols 
regarding treatment strategy in case of suspected early post-
operative infection, and tendency to register procedures in the 
LROI database. We asked, in particular, about type and dura-
tion of antibiotic prophylaxis. This survey showed a variance 
in postoperative duration of antibiotic prophylaxis. 10 Dutch 
hospitals administered a single-shot antibiotic prophylaxis, 
while the remaining 89 administered a multiple-shot antibi-
otic prophylaxis. This variance facilitated an observational 
cohort study using the LROI. The LROI has a completeness of 
over 95% for primary hip and knee arthroplasties and of 91% 
and 92% for the hip and knee revision procedures respectively 
(Dutch Arthroplasty Register [LROI] 2014, 2017, van Steen-
bergen et al. 2015). The translated survey form can be found 
in Appendix 1, Supplementary data. 
Each patient who had a primary THA or TKA was followed 
up for a minimum of 12 months until the end of the obser-
vation period (December 31, 2015) or until the date of 1- or 
2-stage revision for infection, revision for another indication, 
death or end of follow-up (January 1, 2018). Revisions for 
infection included only complete revision of the total system, 
obtained by a 1- or 2-stage revision procedures. All partial 
revisions (e.g., debridement, antibiotics, and implant reten-
tion procedures [DAIR]) were excluded because these partial 
revisions are inconsistently recorded compared with total revi-
sions (Dutch Arthroplasty Register [LROI] 2017, Veltman et 
al. 2018). We chose to end the follow-up period at 1 year after 
surgery as with longer follow-up the influence of hematog-
enous infections on the measured outcome may increase to 
become larger than the influence of the duration of antibiotic 
prophylaxis at primary surgery. 
We defined infection status using the surgical indication 
reported on the LROI revision arthroplasty form following sur-
gery by the treating orthopedic surgeon. We included patients 
whom had undergone complete revision captured by the LROI 
where the reason for revision was defined as infection in the 
infected group and patients in whom the reason for revision 
was not reported, or reason for revision other than infection 
was reported, in the non-infected group. The diagnosis and 
treatment strategy for complete revision for infection was at 
the discretion of the surgeon and treating unit and it reflected 
contemporary practice over the study period, with raised 
inflammatory markers, joint-specific symptoms, sinuses, and 
positive microbiological cultures being common diagnostic 
features over that period (Parvizi et al. 2013). 
We compared the risk of complete revision surgery for 
infection in the 1st year following primary arthroplasty by the 
type and duration of antibiotic prophylaxis regimen admin-
istered at primary surgery. We considered the patient char-
acteristics age, sex, BMI, ASA grade, and previous surgery. 
We considered surgical factors such as indication for surgery, 
surgical approach, type of fixation, and bearing surface. Data 
from the LROI database were combined at hospital level with 
the results of the national survey on antibiotic prophylaxis. 
Results of the survey show there were 3 types of antibiotic 
regimens that are used in the Netherlands: multiple doses of 
cefazolin (MCZ), multiple doses of cefuroxime (MCX), and 
single dose of cefazolin (SCZ), which are all in concordance 
with the Dutch guideline for perioperative antibiotics in total 
hip and knee arthroplasty (Veltman et al. 2018). No other anti-
biotic regimens were encountered in the survey. Patients were 
divided into 3 groups (MCZ, MCX, and SCZ) according to 
the antibiotic prophylaxis protocol of the hospital where they 
were treated.
Statistics
We investigated the association between hospital antibiotic 
prophylaxis regimen policies (MCZ used as the reference) 
and the risk of complete revision for infection in the first 12 
months following the index primary surgery with Poisson 
regression to account for time at risk and to produce hazard 
ratios including 95% confidence intervals (CI). The baseline 
hazard rate was modelled with restricted cubic splines. The 
optimum numbers of knots (3 degrees of freedom [d.f.] for the 
hip models, 4 d.f. for the knee models) was identified with AIC 
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and BIC criteria (Appendix Table 1, Supplemen-
tary data). Interaction terms between the splines 
and the main exposure covariates were included 
to estimate the time-dependent hazard ratio for 
complete revision for infection of the different 
antibiotic prophylaxis regimens (Royston and 
Lambert 2011). Huber–White sandwich esti-
mates of variance were computed to adjust for 
within-hospital correlation. The models were 
stratified by surgical site and adjusted for age, 
sex, BMI, and ASA classification. Multiple 
imputation by chained equations (5 imputations 
sets) under a missing at random framework was 
used to account for missing data. The imputation 
model incorporated the PJI status, time at risk, 
the main exposure, the aforementioned adjust-
ment factors and indication for surgery, surgical 
approach, method of fixation, bearing surface, 
and year of surgery as ancillary variables. All 
statistical analyses were performed using Stata, 
version 15.1 (StataCorp, College Station, TX, 
USA).
Ethics, registration, funding, and potential 
conflicts of interest
This study was approved by the scientific com-
mittee of the LROI. The database was con-
structed by the LROI office. All data provided by 
the LROI were anonymized, no patient identifi-
able data were available to the researchers. 
The study protocol was registered on Clinical-
Trials.gov (reference NCT03348254).
This study was partially supported by the 
NIHR Biomedical Research Centre at Univer-
sity Hospitals Bristol NHS Foundation Trust and 
the University of Bristol. The views expressed 
in this publication are those of the author(s) and 
not necessarily those of the NHS, the National 
Institute for Health Research, or the Department 
of Health and Social Care.
The National Institute for Health Research had 
no role in study design, data collection analysis, 
interpretation, or writing of the report. The cor-
responding author had full access to all the data 
in the study and had final responsibility for the 
decision to submit for publication. The authors 
have no conflicts of interest to declare.
Results
During 2011 to 2015, 130,712 primary total hip 
arthroplasties and 111,467 primary total knee 
arthroplasties were performed across 99 centers. 
Figure 1. Rate of complete revision for 
infection in the first 12 months following 
primary hip replacement by type of antibi-
otics regimen.
Figure 2. Rate of complete revision for 
infection in the first 12 months following 
primary knee replacement by type of anti-
biotics regimen.
Figure 3. Hazard ratio and 95% CI* of complete revision for infection in the first 12 
months following primary hip replacement by type of antibiotics regimen (reference: 
cefazolin multiple dose). * Derived from unadjusted Poisson model with restricted cubic 
splines (3 degree of freedom) (see Appendix Table 2).
Figure 4. Hazard ratio and 95% CI* of complete revision for infection during the first 12 
months following primary knee replacement by type of antibiotics regimen (reference: 
cefazolin multiple dose). *Derived from unadjusted Poisson model with restricted cubic 
splines (3 degree of freedom) (see Appendix Table 3).
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(adjusted HR MCX vs. MCZ at 3 months 1.7 [0.54–5.4], at 
6 months 1.2 [0.65–2.0], at 12 months 1.9 [0.56–6.1]). The 
patterns observed were comparable in the unadjusted and 
adjusted models (Tables 1 and 2).
Discussion
In this large observational cohort study of primary total hip 
and knee replacement, our findings suggest a comparable risk 
of complete revision for infection between the antibiotic pro-
phylaxis regimens in terms of type of antibiotic and duration 
of prophylaxis during the first 12 months following surgery. 
When examining the hazard ratios, it is important to note that 
the majority of infections occurred within the first 3 months 
of surgery. Comparing single and multi-dose prophylaxis 
with cefazolin for hip replacement, the hazard ratio for com-
plete revision for infection following single-dose prophylaxis 
steadily increased over time from less than half of that with 
multi-dose to over double the incidence of infection by month 
12. This may be due to low-virulence micro-organisms that 
are more susceptible to multi-dose therapy presenting with 
infection later. If this is true, the differences between the dif-
ferent regimes should become more apparent with longer 
follow-up. This was not the case following knee replacement 
and alternatively may simply reflect either a chance occur-
rence, differences in patient- and surgery-related factors, or 
residual confounding. Adjustment for established confound-
ing variables (age, sex, BMI, ASA grade) did not change 
these results.
We observed that the highest risk of complete revision for 
infection in the year following surgery occurred within the 
399 hips and 303 knees were revised within 1 year of the pri-
mary arthroplasty for an indication of infection (Tables 2 and 3, 
see Supplementary data). Multiple-dose cefazolin (MCZ), mul-
tiple-dose cefuroxime (MCX), or single-dose cefazolin (SCZ) 
antibiotic prophylaxes were respectively administrated to 87%, 
4%, and 9% of patients. Hereafter, “revision” refers to “1 and 
2-stage revisions.” 
For total hip arthroplasties, the 1-year rates of revision for 
infection (CI) were respectively 31/10,000 person-years (28–
35), 39 (25–59), and 23 (15–34) in the groups that received 
MCZ, MCX, and SCZ; the rates for knee arthroplasties were 
27 (24–31), 40 (24–62), and 24 (16–36) respectively. The rates 
of revision for infection over time according to antibiotic pro-
phylaxis regimen are shown in Figures 1 and 2. Revision for 
infection was performed most frequently in the first 3 months 
postoperatively for both hip and knee replacements. 
While the risk of complete revision for infection appeared 
to differ over time, no or little evidence of differences between 
antibiotic prophylaxis regimens was found (Figures 3 and 4). 
In the first 11 months after primary hip arthroplasty, the risk 
of revision was comparable between SCZ and MCZ (adjusted 
HR SCZ vs. MCZ at 3 months 0.59 [0.19–1.8], at 6 months 
1.02 [0.43–2.4]), but the risk of revision was higher in the SCZ 
group thereafter (HR 2.2 [1.1–4.4]). No evidence of difference 
was found between MCZ and MCX following hip arthroplasty 
(adjusted HR MCX vs. MCZ at 3 months 1.5 [0.77–3.1], at 
6 months 1.0 [0.60–1.7], at 12 months 0.61 [0.20–1.8]). For 
patients receiving a primary total knee arthroplasty revision 
rates between SCZ and MCZ were comparable (adjusted HR 
SCZ vs. MCZ at 3 months 1.8 [0.87–3.8], at 6 months 0.89 
[0.15–5.3], at 12 months 0.47 [0.09–2.4]). The risk of revision 
for infection was also comparable between MCZ and MCX 
Table 1. Hazard ratio (HR) of complete revision for infection in 
the first 12 months following primary hip replacement (reference: 
cefazolin multiple dose)
 cefazoline cefuroxime
Months from single dose multiple dose
primary procedure HR (95% CI) HR (95% CI)
Unadjusted HR
   1 0.45 (0.17–1.20) 1.82 (0.92–3.62)
   2 0.50 (0.17–1.42) 1.92 (0.92–4.01)
   3 0.60 (0.19–1.87) 1.59 (0.78–3.25)
   6 1.04 (0.43–2.49) 1.03 (0.61–1.74)
   9 1.59 (0.82–3.09) 0.76 (0.36–1.61)
 12 2.18 (1.09–4.38) 0.61 (0.21–1.78)
Adjusted HR a
   1 0.45 (0.17–1.20) 1.80 (0.92–3.52)
   2 0.49 (0.17–1.38) 1.88 (0.92–3.86)
   3 0.59 (0.19–1.79) 1.54 (0.77–3.08)
   6 1.02 (0.43–2.39) 1.00 (0.60–1.68)
   9 1.59 (0.83–3.02) 0.75 (0.35–1.61)
 12 2.21 (1.12–4.38) 0.61 (0.20–1.81)
a Adjusted for age, sex, BMI, and ASA grade.
Table 2. Hazard ratio (HR) of complete revision for infection in the 
first 12 months following primary knee replacement (reference: 
cefazolin multiple dose)
 cefazoline cefuroxime
Months from single dose multiple dose
primary procedure HR (95% CI) HR (95% CI)
Unadjusted HR
   1 0.78 (0.33–1.84) 2.24 (0.48–10.5)
   2 1.52 (0.78–2.95) 2.70 (1.15–6.30)
   3 1.77 (0.86–3.63) 1.72 (0.54–5.50)
   6 0.89 (0.15–5.26) 1.13 (0.66–1.91)
   9 0.58 (0.26–1.26) 1.36 (0.59–3.11)
 12 0.47 (0.09–2.40) 1.88 (0.58–6.10)
Adjusted HR a
   1 0.78 (0.33–1.83) 2.34 (0.49–11.2)
   2 1.55 (0.80–3.02) 2.70 (1.16–6.29)
   3 1.81 (0.87–3.76) 1.71 (0.54–5.37)
   6 0.89 (0.15–5.31) 1.15 (0.65–2.02)
   9 0.58 (0.26–1.28) 1.38 (0.58–3.30)
 12 0.47 (0.09–2.37) 1.88 (0.56–6.31)
a Adjusted for age, sex, BMI, and ASA grade
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first 3 months after the operation. Rates then appear to rise 
again towards the end of the follow-up period. These patterns 
are consistent with contemporary patterns found in other reg-
istries (Dale et al. 2012, Lenguerrand et al. 2017a, 2017b). 
This may be due to the effect of more virulent microorganisms 
presenting during the first 3 months and less virulent micro-
organisms presenting later. Since the LROI does not provide 
data on which microorganism is causing the PJI, this remains 
speculative. Another reason might be a genuine increase in 
the incidence of PJI or may reflect more rapid diagnosis and 
aggressive treatment of PJI in recent years. We have not ana-
lyzed procedures where only debridement or partial revision 
(including debridement and implant retention [DAIR] with 
modular exchanges) were performed as these procedures are 
not reliably captured by the LROI registry (Veltman et al. 
2018). DAIR has been shown to treat infection effectively in 
approximately 46–76% of cases (Wouthuyzen-Bakker et al. 
2020). We have no reason to believe that the use of DAIR is 
related to type or duration of antibiotic prophylaxis, but it is a 
possible cause of residual confounding.
It has been suggested that the most appropriate periopera-
tive prophylactic antibiotic is a first- or second-generation 
cephalosporin (i.e., cefazolin or cefuroxime) administered 
intravenously within 30 to 60 minutes prior to incision as a 
single and weight-adjusted dose (AlBuhairan et al. 2008, Ste-
fansdottir et al. 2009, Steinberg et al. 2009). This policy is 
part of antibiotic stewardship, performed in countries with a 
low prevalence of MRSA (Illingworth et al. 2013, American 
Academy of Orthopaedic Surgeons/American Association of 
Orthopaedic Surgeons 2014). While consensus exists on type 
of antibiotic prophylaxis (Parvizi and Gehrke 2018) the post-
operative duration of antibiotic prophylaxis remains subject 
to discussion. 
A recent systematic review and meta-analysis by Thorn-
ley et al. (2015) explored whether or not a single preopera-
tive antibiotic dose is adequate for arthroplasty patients. The 
review included 4 RCTs including 4,036 patients (Heydemann 
and Nelson 1986, Ritter et al. 1989, Wymenga et al. 1992, 
Kanellakopoulou et al. 2009). They concluded that additional 
postoperative antibiotic doses did not reduce the rates of infec-
tions (3.1% versus 2.3% postoperative PJI for multiple-dose 
and single-dose prophylaxis respectively). However, they 
reported that the quality of the included studies was very low. 
3 of these studies were performed more than 20 years ago, 
while the other study used teicoplanin, which is no longer rec-
ommended for use as antibiotic prophylaxis (Berrios-Torres 
et al. 2017). Heydemann and Nelson (1986) randomized 211 
patients between single-dose and 48-hour multiple-dose pro-
phylaxis, but found no cases of PJI in either group. Ritter et al. 
(1989) compared a single dose of cefuroxime to 24 hours of 
postoperative prophylaxis in 196 patients, and found no cases 
of PJI in either group. Wymenga et al. (1992) randomized 
3,013 patients in a multicenter RCT comparing a single preop-
erative dose of cefuroxime to a group receiving three doses and 
found no significant differences in PJI rates between groups. 
Engesaeter et al. (2003) reported the lowest rate of infection 
for patients who received 4 doses of antibiotic prophylaxis 
in 24 hours, compared with patients who received 1, 2, or 3 
doses in their study of the Norwegian Arthroplasty Register. 
All authors of these studies recognized their study sample to 
be underpowered for determining a difference in PJI rates and 
recommended further studies to provide a definite answer. 
Based on these studies, the CDC has recently recommended 
against the use of postoperative continuation of antibiotic pro-
phylaxis (Berrios-Torres et al. 2017). The recent International 
Consensus meeting advises to continue antibiotics postopera-
tively for 24 hours until better quality evidence is available 
(Parvizi and Gehrke 2018). A protocol for an RCT randomiz-
ing patients receiving a total knee arthroplasty between single-
dose versus multiple-dose antibiotic prophylaxis has been reg-
istered on clinicaltrials.gov (NCT03283878). The study aims 
to answer definitively what duration of antibiotic prophylaxis 
is best. However, the planned follow-up of 90 days seems too 
short to capture all relevant infections. Also, the sample size is 
not justified in the trial registration, but with the aim of includ-
ing 8,000 patients the study seems underpowered. 
Our study has several strengths. The large numbers stud-
ied allows adequate power to detect rare outcomes such as 
complete revision for infection. Data capture represents over 
98% of national activity (Dutch Arthroplasty Register 2017). 
This rate of coverage provides excellent external validity and 
generalizability of our findings. The rate of complete revision 
for infection within 1 year of primary arthroplasty is higher 
for males, patients with higher BMI, or higher ASA grade in 
all groups, independent of the type of antibiotic prophylaxis 
(Dale et al. 2012, Lenguerrand et al. 2018). This is in agree-
ment with the literature and highlights the comparability of 
this Dutch arthroplasty cohort to other studied cohorts (Dale 
et al. 2012, Lenguerrand et al. 2018, Kunutsor et al. 2018b).
In order to establish the current practice for antibiotic pro-
phylaxis regimes, we conducted a comprehensive national 
survey to determine current practice. The outcome of interest 
is a binary endpoint, and whilst this may mean that not all cases 
of PJI are captured, as many may be treated without complete 
revision surgery, it does make the end-point easily defined 
(Blom et al. 2003). In the absence of randomized controlled 
trials on the type and duration of antibiotic prophylaxis, this 
natural experiment in a large and generalizable national reg-
istry represents the best data currently available to determine 
whether there is a difference in the risk of complete revision 
for infection according to the antibiotic prophylaxis regimen. 
The study does have limitations. The LROI database was 
established as an arthroplasty register, and whilst one of the 
outcomes of interest is complete revision for infection, the 
register was not designed to capture all infection outcomes 
and thus there is likely to be underreporting of infection as 
may also be the case in other national arthroplasty registries 
(Gundtoft et al. 2015, Kunutsor et al. 2018b). The most nota-
6 Acta Orthopaedica 2020; 91 (x): x–x
ble effect of this is the lack of capture of further procedures 
performed after the primary surgery to manage infection, such 
as DAIR procedures. The Dutch survey showed only 64% of 
hospitals registered DAIR procedures in the LROI, thus we 
did not include these in our analysis. As about 50% of PJI 
may be treated only with DAIR and arthroplasty registries are 
known to provide an underestimation of the rate of prosthetic 
revisions due to PJI of 20%, we may be missing as much as 
70% of all treated infections (Gundtoft et al. 2015, Kunut-
sor et al. 2018a). Although prospectively collected our data 
are observational, and we can only draw conclusions on the 
nature and magnitude of the associations but cannot establish 
causative relation due to the possibility of residual confound-
ing and estimation uncertainty. Whilst we conducted a com-
prehensive survey to establish the current practice in terms 
of antibiotic prophylaxis regimes, it is likely that for various 
reasons, including allergy, intolerance, and surgeons’ prefer-
ence, not all patients received the antibiotics as per hospital 
protocol. However, a recent large retrospective study in the 
USA showed that 95% of patients received standard antibi-
otic prophylaxis (Wyles et al. 2019). The three types of anti-
biotics all are cephalosporins with the same allergy profile, 
therefore the percentage of patients with allergies should be 
comparable in all groups. Changes to the local antibiotic pro-
tocols during the study period have not been captured by the 
survey. The Dutch guideline for antibiotic prophylaxis around 
primary hip and knee arthroplasty did not change during the 
time period. However, changes to the antibiotic protocols may 
have occurred between the groups in all directions. Due to the 
quasi-randomized allocation of our patients, this should not 
introduce systematic bias. 
Thus, this study resembles a natural experiment. Rather 
than controlling for observed confounders and expecting no 
unobserved confounders to be present (as in multiple regres-
sion, matching, and reweighting), natural experiments identify 
variation in the exposure, known to be independent of other 
confounders (Bor 2016). In our study quasi-random variation 
in the exposure (antibiotic prophylaxis regimen after total hip 
or knee arthroplasty) arises from naturally occurring random 
variation due to allocation of patients to the regional hospital 
near their residence. Natural experiments minimize the risk of 
confounding due to selective exposure to the intervention or 
residual confounding, and have internal validity and transpar-
ency of assumptions (Bor 2016). To establish true causality, 
a superiority or non-inferiority randomized controlled trial is 
still needed. However, as PJI is rare, the numbers needed for 
such a trial would be very large. Nonetheless, as the impact 
of PJI is so devastating (Moore et al. 2015) we recommend 
that such a trial is undertaken and suggest that embedding 
such a trial in a national arthroplasty registry may reduce costs 
and improve feasibility. Until such time, the data represented 
here are the best available evidence and it must be questioned 
whether there is any advantage to the use of prolonged antibi-
otic prophylaxis beyond a single dose.
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